We have evaluated the clinical utility and blood propofol concentratio
ns produced with two different infusion regimens for propofol, given t
o supplement 67% nitrous oxide-morphine anaesthesia. Patients received
a standardized three-step infusion of propofol based either on body w
eight (weight-corrected group) or on a mean body weight of 70 kg (stan
dard dose group). Both groups showed similar cardiovascular stability
and recovery times. In the 48 patients studied, isoflurane was used as
a supplement in nine (two in the weight-corrected group). Apparently
steady state blood propofol concentrations were 3.41 (SD 0.69) mu g ml
(-1) in the weight-corrected group and 3.46 (0.79) mu g ml(-1) in the
standard dose group. These results suggest that for patients weighing
60-90 kg body weight, a standard dose infusion regimen may be a suitab
le starting point. In routine clinical practice, the need for isoflura
ne supplementation may be avoided by subsequent titration of the infus
ion rate according to clinical response. Computer simulation of the ac
tual infusion rates used in each patient has allowed retrospective com
parison of the predictive performance of different pharmacokinetic des
criptors for propofol. The variables described by Tackley and colleagu
es provided a more accurate prediction of the measured blood propofol
concentration than did the variable set reported by Gepts and colleagu
es.